$100 million more from Gates

The linkurl:Bill & Melinda Gates Foundation;http://www.the-scientist.com/article/display/25259/ has established a new five-year $100 million fast-track grant program for global health research. Each project will receive $100,000, with the option of additional funding if merited. The program, which will adopt a fast-track review, is for scientists with "creative concepts" to fight global health scourges affecting developing countries, such as vaccines, drugs, and diagnostics. One of the

| 1 min read

Register for free to listen to this article

Listen with Speechify

0:00

1:00

Share

The linkurl:Bill & Melinda Gates Foundation;http://www.the-scientist.com/article/display/25259/ has established a new five-year $100 million fast-track grant program for global health research. Each project will receive $100,000, with the option of additional funding if merited. The program, which will adopt a fast-track review, is for scientists with "creative concepts" to fight global health scourges affecting developing countries, such as vaccines, drugs, and diagnostics. One of the goals of the initiative is to "support paradigm-changing ideas that have never before been tested, and that might not stand up to traditional peer review." To expedite the review process, funding proposals should be "relatively short" and can avoid preliminary data, they will be reviewed within three months, and grants can be awarded several times per year. The first call for proposals will appear in early 2008, on the linkurl:Grand Challenges in Global Health;http://www.gcgh.org/channels/gcgh Web site. James Aiken, President and Chief Executive Officer, Keystone Symposia on Molecular & Cellular Biology, took it upon himself to send an Email about the program to Keystone participants: "Keystone Symposia never shares, and only rarely uses our mailing lists for anything other than Keystone Symposia business. In this case, however, I felt that this new opportunity for grants was something that most of our participants would like to know about."

Interested in reading more?

Placeholder Image

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Meet the Author

Alison McCook
This person does not yet have a bio.
View full profile

Share

Related Research Resources

TS Digest January 2025

January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Sex Differences in Neurological Research

Sex Differences in Neurological Research

Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.

New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.

New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.

Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research

Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.

Products

Product News

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development

Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.

We’ve updated our Privacy Policy to make it clearer how we use your personal data.

Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.